Founded in 2012, Rightongene Biotechnology is an established life technology company that develops, manufactures and markets molecular diagnostic and immunodiagnostic products and systems. Its mission is to provide accurate gene and antigen detection for patients with leukemia, lymphoma, solid tumors and infectious diseases. This helps to provide accurate formulation of individualized treatment plans and efficacy monitoring for patients on the basis of their diagnostic, prognostic and risk stratification information.
At present, the company has been granted with patent rights on 29 inventions. In particular, the company has independently researched and developed the super sensitive digital droplet PCR (S-ddPCR) detection kit and full-spectrum flow cytometry calculation model, that enables analytical sensitivity in the range between 0.05% to 0.001%. This significantly expands the prospect of clinical application of liquid biopsy for early tumor detection.
The company also has twenty-nine molecular diagnostic reagent been regulatory approved as Class III medical devices by the China NMPA. In 2012, the company was approved with the first molecular diagnostic reagent product for leukemia with the NMPA nationally, which lead the market for 6 years ahead of its competitor with similar diagnostic product. More recently in September 2020, the company was once again the first to obtain Class III regulatory approval for molecular diagnostic reagent product for lymphoma detection.
The company has a well-established national sales network that enables its hematopoietic disease detection products to reach 71 of the top 100 blood disease hospitals in the country and its solid tumor detection reagents to reach 69 of the top 100 tumor hospitals in the country. Collectively, this ensures the sales scope covers more than 150 Grade 3A hospitals nationwide.
| Full name | Shanghai Rightongene Biotechnology Co., Ltd. |
|---|---|
| Abbreviations | Righton Gene |
| Code | 688217 |
| Founded | 2012-02-17 |
| Listing | 2021-05-17 |
| Domicile | Shanghai |
| Website | — |
| zqswb@rightongene.com | |
| STAR Theme | Biomedicine |
| CSRC Sector | Pharmaceutical manufacturing |
| Has weighted voting rights structure? | No |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | 0.93 | 0.86 | 0.35 |
| R&D expenditure as a % of operating revenue | 26.10% | 26.23% | 23.76% |
| Operating Revenue | 284,925,965.97 | 255,479,024.24 | 224,443,331.56 |
| Net Income | 38,817,741.75 | 35,947,717.05 | 14,576,759.08 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 284.93 | 255.48 | 224.44 |
| Operating Costs | 248.48 | 214.05 | 181.50 |
| Operating Income | 40.06 | 37.45 | 17.84 |
| Pretax Income | 40.09 | 37.09 | 16.88 |
| Income Tax | 1.27 | 1.14 | 2.30 |
| Net Income | 38.82 | 35.95 | 14.58 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 389.11 | 375.40 | 375.53 |
| Non-current Assets-Total | 322,61 | 280,42 | 242,07 |
| Total Assets | 711,71 | 655,81 | 617,61 |
| Liabilities | |||
| Current Liabilities-Total | 37,52 | 39,98 | 38,28 |
| Non-current Liabilities-Total | 12,40 | 7,86 | 7,31 |
| Total Liabilities | 49,92 | 47,84 | 45,58 |
| Stockholder's Equity | |||
| Share Capital | 41.68 | 41.68 | 41.68 |
| Retained Profits | 68.35 | 29.64 | -6.31 |
| Total Owners' Equity | 661.79 | 607.97 | 572.02 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | 70.11 | 11.68 | -293.60 |
| Net Cash Flows-Investing | -49.33 | -37.68 | -94.11 |
| Net Cash Flows-Financing | -10.84 | -7.57 | 103.81 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| Xiong Hui | 10,176,397 | 18.31% |
| Zhejiang healthcare-fund | 6,251,559 | 11.25% |
| Shanghai Boci Investment Partnership（Limited Partnership） | 4,924,723 | 8.86% |
| Hangzhou Ruihong Investment Partnerships (Limited Partnerships) | 2,845,100 | 5.12% |
| Euro Right Limited | 2,165,042 | 3.90% |
| Shanghai Liyang Investment Partnership（Limited Partnership） | 2,000,000 | 3.60% |
| Shanghai Chenhe Investment Center L.P. | 1,616,564 | 2.91% |
| Tianjin Kangshiyunda Medical Technology Development Partnership (Limited Partnership) | 1,465,734 | 2.64% |
| Shanghai Lianjing Investment Management Center | 1,299,025 | 2.34% |
| Suzhou Chenzhide Investment L.P. | 1,291,997 | 2.32% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.